The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Trump fails to overturn E. Jean Carroll’s $83 million verdict
By Jonathan Stempel NEW YORK (Reuters) – A federal appeals court on Monday refused to throw out an $83.3 million…
Samsung hit with $191.4 million US jury verdict in OLED patent trial
By Blake Brittain (Reuters) -Samsung Electronics owes patent owner Pictiva Displays $191.4 million in damages for infringing two U.S. patents covering…
Nuclear’s Second Act: Energy Stocks Set to Soar Before 2026
The world is quietly entering a new nuclear age. As electricity demand spikes from AI, EVs, and global manufacturing, countries are…